There are 2789 resources available
1286P - Senescent immune phenotype (SIP) status predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients
Presenter: Marie Naigeon
Session: ePoster Display
1287P - Immune T-cell subpopulations from the peripheral blood of non-small cell lung cancer patients are associated with the efficacy of anti-PD-1 immunotherapy
Presenter: Jacobo Rogado
Session: ePoster Display
1173P - Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC
Presenter: Waleed Kian
Session: ePoster Display
1084P - PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma
Presenter: Caroline Robert
Session: ePoster Display
1085P - Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors
Presenter: Elizabeth Burton
Session: ePoster Display
1210P - Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)
Presenter: Baohui Han
Session: ePoster Display
1211P - Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion
Presenter: Sai-Hong Ou
Session: ePoster Display
1254P - Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC
Presenter: Marina Chiara Garassino
Session: ePoster Display
1255P - Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
Presenter: Niels Reinmuth
Session: ePoster Display